Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.In a continued effort to exploit a market estimted to be worth around GBP10 billion, pharmaceuticals giant GlaxoSmithKline is said to be planning to double the manufacturing capacity of its flu vaccine, Fluarix, at its Dresden, Germany-based factory.
Subscribe to our email newsletter
The reports come a few days after the company revealed that it was launching five new vaccines by the year 2010.
Now it seems the company is looking to boost production of its Fluarix drug as it prepares to launch the product in the US. As part of the campaign, Glaxo is reported to be investing up to 100 million euros ($114m) in the Dresden plant and is expected to create over 100 jobs to maximize output.
The goal is to upgrade the manufacturing capacity to 80 million doses a year by 2008.
Glaxo filed an application with the FDA in May to sell its Fluarix shot in the 2005/6 flu season, when it hopes to supply 10-12 million doses to the US. It had originally put off the drug’s launch in the US back in 1992 because it claimed the market was crowded.